Compare iShares MSCI Japan ETF (EWJ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs TG Therapeutics Inc — how do they compare? iShares MSCI Japan ETF trades at $91.84, while TG Therapeutics Inc trades at $54.82 (market cap $8.64B). Which is the better fit depends on your goals.
| EWJ | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $96.97 | $59.06 |
52-Week Low | $71.81 | $26.39 |
Market Cap | — | $8.64B |
Enterprise Value | — | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $91.92, down 2.1% on the day, with a bullish technical signal from moving averages but neutral oscillators. The fund provides exposure to Japanese equities amid a weakening yen, with news highlighting potential currency intervention by Japanese authorities and domestic investment pushes. Recent performance reflects Nikkei 225 volatility, trading near all-time highs before recent pullbacks.
Outlook hinges on yen stability and Japanese economic policies, with opportunities in hedged alternatives to mitigate currency risk. Risks include FX volatility, geopolitical tensions, and Japan's debt burden. Analyst sentiment is mixed, focusing on currency dynamics and equity market resilience.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
